Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight ...

Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence ...

BMB Munai, Inc. announced initial production results of testing one of four pay zones on the Kariman-2 well. BMB Munai, Inc. announced initial production results of testing one of four pay zones on ...

BMB-101, the Company’s novel scaffold 5-HT 2C Gq-protein biased agonist, demonstrated a complete elimination of drop attacks in the DBA/2 mouse model. “DBA/2 is an excellent model for understanding ...